Press release

Interim Report April-June 2018

July 13, 2018 Regulatory
“General knowledge and understanding of Oncopeptides and our clinical strategy has greatly increased during the spring”

Summary of Q2

Financial overview April 1 – June 30 2018

  •  Net sales amounted to 0.0 (0.0) MSEK
  •  Loss for the period was 143.1 (loss: 67.3) MSEK
  •  Loss per share, before and after dilution, was 3.27 (loss: 1.69) SEK
  •  On June 30 cash and cash equivalents amounted to 568.2 (535.1) MSEK

Significant events during the period April 1 to June 30 2018

  •  First patient started treatment with Ygalo® in the Phase I/II study ANCHOR
  •  A Clinical Advisory Board consisting of internationally recognized researchers within the field of clinical development of hematology treatments was formed
  •  Updated interim data with Ygalo® from the ongoing HORIZON – trial (RRMM patients without any remaining treatment options) was presented at the European Hematology Association (EHA) meeting in Stockholm showing an Overall Response Rate (ORR) of 32.1% and a Clinical Benefit Rate (CBR) of 39.3%

Financial overview of the group

2018 2017 2018 2017 2017
SEK thousand  Apr-Jun  Apr-Jun  Jan-Jun  Jan-Jun  Jan-Dec 
Net sales
Operating loss -143,075 -67,260 -205,107 -129,343 -247,620
Loss before tax -143,075 -67,260 -205,107 -129,343 -247,620
Loss for the period -143,075 -67,260 -205,107 -129,343 -247,620
Earnings per share before and after dilution (SEK) -3.27 -1.69 -4.91 -3.54 -6.44
Cash flow from operating activities -96,479 -72,023 -130,607 -139,660 -271,497
Cash and cash equivalents at the end of the period 568,212 535,069 568,212 535,069 404,050
Research & development costs/operating expenses % 69% 74% 75% 75% 80%

Financial calendar
Interim report Q3: October 26
Year-end report 2018: February 22, 2019
For further information, please contact:

Jakob Lindberg, CEO, Oncopeptides
Telephone: +46 (0)8 615 20 40

Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone: +46 (0)70 853 72 92

About Oncopeptides
Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. The company focus on the development of the lead product candidate Ygalo®, an alkylating peptide, Peptidase Enhanced Compounds (PEnCs). Ygalo® is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from treatment with Ygalo® compared with established alternative drugs for patients with late-stage multiple myeloma. Ygalo® will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on July 13, 2018, at 08.00 (CET).

Visit for more information.